StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables

QuarterlyAnnual
Latest, Q2 2026
2,771
Period ended Jun 30, 2026
Change on a year earlier
-15.0%
3,261 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
27
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,771-15.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20263,240-0.2%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20253,044-2.8%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20253,214+2.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20253,261+3.4%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20253,245+7.7%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20243,132+16.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20243,152+17.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20243,153+17.9%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20243,012+19.1%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20232,698+18.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20232,683+14.3%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20232,675+13.7%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20232,530+14.6%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20222,281+13.9%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20222,348+12.8%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up cardiovascular, renal & metabolism (cvrm) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_cvrm_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.